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Physicians evaluation mismatched with Framigham for 50% of the patients
and 27% were under-evaluated. Evaluation mismatched with SCORE for 53%
of the patients, 38% were under-evaluated. Within the 25% of the patients
having a Framingham score >20% and without a lipid lowering treatment,
70% was under evaluated by physicians. Within the 38% of the patients
having a SCORE calculation 5% and without a lipid lowering treatment, 78%
were under evaluated.
 
Conclusion: 
 
This study underlines the mismatch between GP perceived
CVR and calculated CVR, especially for high CVR patient. Males, patients
with treated HBP and with high LDL-c were at increased risk of CVR under-
evaluation.
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Background:
 
 The French guidelines recommend dual antiplatelet therapy
after acute myocardial infarction (MI). 
 
Purpose:
 
 To estimate persistence of dual antiplatelet therapy after MI.
Methods: A cohort study was conducted using data from the main French
health insurance reimbursement database of the Aquitaine region (southwest
France). Patients who have been hospitalized for MI in 2008 were first iden-
tified. Then, we looked for their reimbursement form of dual antiplatelet
therapy (aspirin+clopidogrel) treatment for the following 12 months. Adher-
ence was assessed by using two parameters: proportion of days covered by
the treatment (medication availability) and persistence. The treatment persis-
tence was the percentage of patients still treated at the end of the period.
Discontinuation was defined as a minimum gap of 30 days between the the-
oretical end date of prescription reimbursed (based on a days’ supply) and
the starting date of the next one. 
 
Results:
 
 Among the 634 patients identified, 40 had no reimbursement
of dual antiplatelet therapy immediately after discharge. At three month,
15.2% of the remaining patients did not buy at least one of the two treat-
ments. They were 48.2% at 12 months although the medication availability
was 90%. Conclusion: Theses results suggest that while the patients have
good medication availability, the treatment is often stopped before one
year. At three months after MI, 20.6% of the patients were no longer
treated with dual antiplatelet therapy. The results presented are likely to be
an underestimation of adherence since some patients who buy their treat-
ment, may not take it. This could explain some “resistance” described to
antipletelet therapy.
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Purpose:
 
 Chronic Obstructive Pulmonary Disease (COPD) is expected to be
the third cause of mortality in the world in 2020. Paradoxically, this disease is
widely underdiagnosed and its prevalence remains relatively unknown, in partic-
ular in people at cardiovascular risk for whom the association with COPD may
worsen the prognosis. The aim of this study was to assess COPD prevalence in a
population at cardiovascular risk and to analyse determinants of COPD.
 
Methods: 
 
Our study was based on patients referred for cardiovascular
check-up to a Preventive Cardiology Clinic in a University Hospital in 2009.
Participants answered to questionnaires on socio-economic level, medical his-
tory and life style. They completed an extensive physical examination and a
spirometry test. COPD prevalence was based on the spirometric classification
proposed by the Global Initiative for chronic Obstructive Lung Disease. Deter-
minants of COPD were assessed with logistic regression. 
 
Results:
 
 The sample comprised 502 participants (mean age: 57.4 ±11.1 years),
including 60% of men, 17% of current smokers, 42% of former smokers and 10%
of patients with a history of cardiovascular disease (ischemic heart disease, cere-
brovascular or peripheral arterial disease). Ten-year risk of coronary heart disease
according to the Framingham equation was intermediate (10-20%) for 33% of
patients and high (> 20%) for 5%. After exclusion of asthmatic patients, 5.8%
[95% CI: 3.9% - 8.2%] were spirometrically
 
 
 
screened as COPD patients (Forced
Expiratory Volume in one second / Forced Vital Capacity < 0.70). After adjust-
ment for age, gender and smoking, the odds ratio for COPD was 4.44 [1.83-10.78]
(p-value=0.001) in patients with a history of cardiovascular disease compared to
those without. Besides, 86% of the patients screened with COPD had never been
previously diagnosed.
 
Conclusion:
 
 Patients with cardiovascular disease are at increased risk of
COPD and thus should beneficiate from COPD screening.
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Introduction:
 
 Cardiovascular diseases are the leading cause of mortality in
the western countries at the same time they are beginning to appear with
increasing frequency in developing countries. With the epidemiological transi-
tion phenomenon, Tunisia is now facing the growing prevalence of chronic
diseases. The Tunisian epidemiological data on cardiovascular disease in the
 
Population risk is listed below
 
 Evaluated (%) Framingham (%) Score (%)
Low 
 
40 41 28
 
Medium 
 
37 24 24
 
High
 
23 35 48
 
Explanatory factors for under-evaluation in primary prevention according to 
SCORE 
 
 OR CI 95%
Treated HBP vs no HBP
 
2,55 2.04-3.19
 
Gender (male)
 
2,44 2,16-2,76
 
 LDLc
 
2,13 1,78-2,55
 
Smoker
 
1,82 1,52-2,19
 
Chronic inflammatory disease
 
1,19 1,00-1,42
 
Age
 
1,16 1,15-1,17
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